ClinicalTrials.gg

Program

MK-2214

A development code.

Its studies are mostly in Alzheimer Disease, led by Merck.

Furthest: phase 2, since Jun 13, 20252 company-led studies, 1 open or runningNext primary completion: Apr 30, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck21 open or runningphase 2since Jun 13, 2025Jul 18, 2022Apr 30, 2029phase 2 · NCT07033494
  • Named in Merck’s own pipeline as MK-2214, phase 2, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 18, 2022First study: phase 1 study in Alzheimer DiseaseFirst studyNCT05466422 · 34 enrolled · United States
  2. Jun 13, 2025Phase 2 study in Alzheimer DiseaseNCT07033494 · 340 planned · United States, Argentina, Australia and more

Ahead

  1. Apr 30, 2029Primary completion: phase 2 study in Alzheimer DiseaseNCT07033494

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07033494Alzheimer Disease · United States, Argentina, Australia and more2RecruitingApr 30, 2029340
NCT05466422Alzheimer Disease · United States1CompletedJul 3, 202534

How it is read

Names in the registry

  • “MK-2214”, 2 entries

Codes read as this program: MK2214.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.